<DOC>
	<DOCNO>NCT02525822</DOCNO>
	<brief_summary>The primary objective study compare safety efficacy daily application IDP-123 Lotion Tazorac Cream , 0.1 % , Vehicle Lotion , Vehicle Cream subject moderate severe acne vulgaris .</brief_summary>
	<brief_title>Study Compare Safety Efficacy IDP-123 Lotion Tazorac Cream Treatment Acne Vulgaris</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , vehicle-controlled , 12-week study design assess safety , tolerability , efficacy IDP-123 Lotion comparison Tazorac Cream , Vehicle Lotion , Vehicle Cream subject moderate severe acne . Treatment success evaluate change inflammatory non-inflammatory lesion count , well treatment success use Evaluator 's Global Severity Score . IDP-123 lotion topical treatment acne .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male female least 12 year age old Written verbal informed consent must obtain Subject must score moderate severe Evaluator 's Global Severity assessment Premenses females woman childbearing potential must negative urine pregnancy test screen baseline visit Subjects must willing comply study instruction return clinic require visit Any dermatological condition face could interfere clinical evaluation Any underlying disease ( ) dermatological condition face require use interfere topical systemic therapy make evaluation lesion count inconclusive Subjects facial beard mustache could interfere study assessment Subjects unable communicate cooperate Investigator Subjects underlying disease Investigator deem uncontrolled , pose concern subject safety participate study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>